Zhu Xiao-Hong, Tu Jin-Wei, Dai Ji-Hong
Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/ China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Apr;21(4):393-398. doi: 10.7499/j.issn.1008-8830.2019.04.017.
To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).
A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.
After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024).
For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.
研究丙酸氟替卡松(Flu)、孟鲁司特钠(Mon)和酮替芬(Ket)不同组合治疗咳嗽变异性哮喘(CVA)患儿的临床效果。
选取2015年6月至2018年1月在呼吸内科住院的280例CVA患儿,随机分为Flu+Mon+Ket组、Flu+Mon组、Flu+Ket组、Mon+Ket组、Flu组、Mon组和Ket组,每组40例。各组患儿给予相应药物治疗,疗程均为3个月。治疗2个月和3个月后评估咳嗽情况、咳嗽症状评分、肺功能及药物不良反应。对患儿进行随访观察复发情况。
治疗后,7组患儿咳嗽症状评分均呈下降趋势,第1秒用力呼气容积百分比(FEV1%)和呼气峰值流速预计值百分比(PEF%)均升高。治疗2个月后,Flu+Mon+Ket组咳嗽症状评分显著低于其他组,FEV1%和PEF%显著高于其他组(P<0.05)。治疗2个月和3个月后,Ket组咳嗽症状评分显著高于其他组,FEV1%和PEF%显著低于其他组(P<0.05)。治疗3个月后,其他组咳嗽症状评分、FEV1%和PEF%差异无统计学意义(P>0.05)。7组不良事件发生率均较低,7组间差异无统计学意义(P>0.05)。Ket组咳嗽复发率显著高于其他组(P<0.001),其他组该发生率差异无统计学意义(P>0.0024)。
对于CVA患儿,治疗2个月时,Flu、Mon和Ket联合应用的临床效果优于两药联合及单药治疗,且安全性良好。治疗3个月后,单用Flu或Mon与联合用药效果相似。单用Ket临床效果差,停药后复发率高。